Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1875-6301|12|1|23-36

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.12, Iss.1, 2016-10, pp. : 23-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

By                

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1736-1744

Spandidos Publications

Access to resources Recommend Favorite

STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer

By          

Oncology Reports, Vol. 34, Iss. 3, 2015-01 ,pp. : 1494-1502

Spandidos Publications

Access to resources Recommend Favorite

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells

By                

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 637-646

Spandidos Publications

Access to resources Recommend Favorite

Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma

By                    

Oncology Reports, Vol. 28, Iss. 4, 2012-01 ,pp. : 1200-1204

Spandidos Publications

Access to resources Recommend Favorite

TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

By  

International Journal of Oncology, Vol. 46, Iss. 2, 2015-01 ,pp. : 607-618

Spandidos Publications

Access to resources Recommend Favorite